Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: Results from the PIOace study

Journal of Diabetes Science and Technology

Volumn 5, Issue 4, 2011, Pages 989-998

  Pfützner, Andreas ^a,b   Hanefeld, Markolf ^c   Dekordi, Lida A ^a   Müller, Jürgen ^d   Kleine, Iris ^e   Fuchs, Winfried ^e   Forst, Thomas ^a  

^a IKFE   (Germany)

^b UNIVERSITY OF APPLIED SCIENCES   (Germany)

^c GWT   (Germany)

^d acromion GmbH   (Germany)

^e Takeda Pharma GmbH   (Germany)

Author keywords

Cardiovascular pharmacology; Clinical trial; Hypertension; Inflammation; Pioglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; PIOGLITAZONE; PLACEBO; RAMIPRIL;

ADULT; AGED; ARTICLE; BLOOD; BLOOD VESSEL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HOSPITALIZATION; HUMAN; INFLAMMATION; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; UPREGULATION;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD VESSELS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; MALE; MIDDLE AGED; PLACEBOS; RAMIPRIL; RISK FACTORS; SEVERITY OF ILLNESS INDEX; THIAZOLIDINEDIONES; UP-REGULATION;

EID: 84855365023     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681100500422     Document Type: Article

References (39)

1. Meigs JB. Epidemiology of the metabolic syndrome. Curr Diab Rep. 2003;3(1):73-9.
2. German Diabetes Association, Matthaei S, Bierwirth R, Fritsche A, Gallwitz B, Häring HU, Joost HG, Kellerer M, Kloos Ch, Kunt T, Nauck M, Schernthaner G, Siegel E, Thienel F. Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association. Exp Clin Endocrinol Diabetes. 2009;117(9):522-57.
3. Van Gaal LF, Mertens L, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444:875-80.
4. Forst T, Hohberg C, Pfützner A. Cardiovascular effects of disturbed insulin activity in metabolic syndrome and in type 2 diabetes patients. Horm Metab Res. 2009;41(2):123-31.
5. Bergman RN, Kim SP, Hsu IR, Catalano KJ, Chiu JD, Kabir M, Richey JM, Ader M. Abdominal obesity: role in the pathophysiology of metabolic disease and cardiovascular risk. Am J Med. 2007;120(Suppl 1):S3-8.
6. Ritchie SA, Connell JM. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis. 2007;17(4):319-26.
7. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature. 2006;444(7121):847-53.
8. Cassis LA, Police SB, Yiannikouris F, Thatcher SE. Local adipose tissue renin-angiotensin system. Curr Hypertens Rep. 2008;10(2):93-8.
9. Hanefeld M. Postprandial hyperglycemia: noxious effects on the vessel wall. Int J Clin Pract Suppl. 2002;129:45-50.
10. Home P. Contribution of basal and post-prandial hyperglycemia to micro- and macrovascular complications in people with type 2 diabetes. Curr Res Med Opin. 2005;21(7):989-98.
11. DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Hodis HN, Kitabchi AE, Mack WJ, Mudaliar S, Ratner RE, Williams K, Stentz FB, Musi N, Reaven PD; ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364(12):1104-15.
12. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368(9541):1096-105. Erratum in: Lancet. 2006;368(9549):1770.
13. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inihibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145-53.
14. DREAM Trial Investigators. Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR. The effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355(15):1551-62.
15. Hanefeld M, Marx N, Pfützner A, Baurecht W, Lübben G, Kargiannis E, Stier U, Forst T. Anti-inflammatory effect of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol. 2007;49(3):290-7.
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-9.
17. Hedblad B, Nilsson P, Janzon L, Berglund G. Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmö, Sweden. Diabet Med. 2000;17(4):299-307.
18. Pfützner A, Forst T. High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diab Technol Ther. 2006;8(1):28-36.
19. Langenfeld MR, Forst T, Hohberg C, Kann P, Lübben G, Konrad T, Füllert S, Sachara C, Pfützner A. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation. 2005;111(19):2525-31.
20. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB Sr, Perez A, Provost JC, Haffner SM. Effect of pioglitazone compared with glimepiride on carotid intimamedia thickness in type 2 diabetes: a randomized trial. JAMA. 2006;296(21):2572-81.
21. Forst T, Wilhelm B, Pfützner A, Fuchs W, Lehmann U, Schaper F, Weber M, Müller J, Konrad T, Hanefeld M. Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk. Diab Vasc Dis Res. 2008;5(4):298-303.
22. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochellière R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM; PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299(13):1561-73.
23. Pfützner A, Marx N, Lübben G, Langenfeld M, Walcher D, Konrad T, Forst T. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol. 2005;45(12):1925-31.
24. Hamann A, Garcia-Puig J, Paul G, Donaldson J, Stewart M. Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with type 2 diabetes inadequately controlled on metformin alone. Exp Clin Endocrinol Diabetes. 2008;116(1):6-13.
25. Karagiannis E, Pfützner A, Forst T, Lübben G, Roth W, Grabellus M, Flannery M, Schöndorf T. The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions. Diabetes Technol Ther. 2008;10(3):206-12.
26. Kato T, Sawai Y, Kanayama H, Taguchi H, Terabayashi T, Taki F, Yamada K, Yamazaki Y, Hayakawa N, Suzuki A, Oda N, Katada N, Itoh M. Comparative study of low-dose pioglitazone or metformin treatment in Japanese diabetic patients with metabolic syndrome. Exp Clin Endocrinol Diabetes. 2009;117(10):593-9.
27. Forst T, Karagiannis E, Lübben G, Hohberg C, Schöndorf T, Dikta G, Drexler M, Morcos M, Dänschel W, Borchert M, Pfützner A. Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease. Atherosclerosis. 2008;197(1):311-7.
28. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279-89.
29. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM; PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol. 2007;49(17):1772-80.
30. Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, Dormandy J. PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007;38(3):865-73.
31. Forst T, Pfützner A, Lübben G, Weber M, Marx N, Karagiannis E, Köhler C, Baurecht W, Hohberg C, Hanefeld M. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk - the PIOSTAT Study. Metabolism. 2007;56(4):491-6.
32. Scheen AJ. Prevention of type 2 diabetes through inhibition of the renin-angiotensin system. Drugs. 2005;64(22):2537-65.
33. Negro R, Dazzi D, Hassan H, Pezzarossa A. Pioglitazone reduces blood pressure in non-dipping diabetic patients. Minerva Endocrinol. 2004;29(1):11-7.
34. Giles TD, Sander AG. Effects of thiazolidinediones on blood pressure. Curr Hypertens Rep. 2007;9(4):332-7.
35. Anan F, Masaki T, Fukunaga N, Teshima Y, Iwao T, Kaneda K, Umeno Y, Okada K, Wakasugi K, Yonemochi H, Eshima N, Saikawa T, Yoshimatsu H. Pioglitazone shift circadian rhythm of blood pressure from non-dipper to dipper type in type 2 diabetes mellitus. Eur J Clin Invest. 2007;37(9):709-14.
36. Schöndorf T, Forst T, Hohberg C, Pahler S, Link C, Roth W, Pfützner A. The IRIS III study: pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weight. Diab Obes Metab. 2007;9(1):132-3.
37. Cicconetti P, Donadio C, Pazzaglia MC, D'Ambrosio F, Marigliano V. [Circadian rhythm of blood pressure: non-dipping pattern and cardiovascular risk][Article in Italian]. Recenti Prog Med. 2007;98(7-8):401-6.
38. Zweiker R, Eber B, Schumacher M, Toplak H, Klein W. "Non- dipping"related to cardiovascular events in essential hypertensive patients. Acta Med Austriaca. 1994;21(3):86-9.
39. Kones R. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease - a perspective. Drug Des Devel Ther. 2010;4:383-413.